

Director who reports to the Assistant Secretary for Health.

2. OCCHE shall work with the Immediate Office of the Secretary, Staff Divisions, and Operating Divisions to focus on:

- Identifying communities with disproportionate exposures to climate hazards and vulnerable populations.
- Addressing health disparities exacerbated by climate impacts to enhance community health resilience.
- Promoting and translating research on public health benefits of multi-sectoral climate actions.
- Supporting regulatory efforts to reduce greenhouse gas emissions and criteria air pollution throughout the health care sector, including participating suppliers and providers.
- Fostering innovation in climate adaptation and resilience for people and communities experiencing a disproportionate share of climate impacts and health inequities.
- Providing expertise and coordination to the White House and other Federal agencies related to climate change and health equity deliverables and activities, including executive order implementation, and reporting on health adaptation actions under the United Nations Framework Convention on Climate Change.
- Promoting training opportunities to build the climate and health workforce and empower communities.
- Exploring opportunities to partner with the philanthropic and private sectors to support innovative programming to address disparities and health sector transformation.

#### Delegations of Authority

Directives or orders made by the Secretary or the Assistant Secretary for Health, including all delegations and re-delegations of authority made to officials and employees of affected organizational components will continue in force pending further delegation, if allowed, provided they are consistent with this realignment.

**Andrea Palm,**

*Deputy Secretary.*

[FR Doc. 2021-18794 Filed 8-30-21; 8:45 am]

**BILLING CODE 4150-03-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Advancing Translational Sciences; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Center for Advancing Translational Sciences Advisory Council.

The meeting will be open to the public as indicated below. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov>). Individuals who need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Advancing Translational Sciences Advisory Council.

*Date:* September 23–24, 2021.

*Closed:* September 23, 2021, 10:30 a.m. to 12:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Center for Advancing Translational Sciences, National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Room 987/989, Bethesda, MD 20892 (Virtual Meeting).

*Open:* September 23, 2021, 1:00 p.m. to 5:00 p.m.

*Agenda:* Report from the Institute Director and other staff.

*Place:* National Center for Advancing Translational Sciences, National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Room 987/989, Bethesda, MD 20892 (Virtual Meeting).

*Open:* September 24, 2021, 1:00 p.m. to 5:00 p.m.

*Agenda:* To view and discuss Clearance of Concepts.

*Place:* National Center for Advancing Translational Sciences, National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Room 987/989, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Anna L. Ramsey-Ewing, Ph.D., Executive Secretary, National Center

for Advancing Translational Sciences, One Democracy Plaza, Room 1072, Bethesda, MD 20892, 301-435-0809, [anna.ramseyewing@nih.gov](mailto:anna.ramseyewing@nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice no later than 15 days after the meeting at [NCATSCouncilInput@mail.nih.gov](mailto:NCATSCouncilInput@mail.nih.gov). The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: August 25, 2021.

**David W. Freeman,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-18727 Filed 8-30-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Submission for OMB Review; 30-Day Comment Request; Evaluation of Office of Acquisitions System (OASYS) and FFRDC Contract Administration System (FCAS) Vendor Portals National Cancer Institute (NCI)

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

**DATES:** Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.

**FOR FURTHER INFORMATION CONTACT:** Marla Jacobson, 9609 Medical Center Drive, MSC 9742, Rockville, MD 20850 or call non-toll-free number 240-276-

5267 or Email your request, including your address to: [marla.jacobson@nih.gov](mailto:marla.jacobson@nih.gov). Formal requests for additional plans and instruments must be requested in writing.

**SUPPLEMENTARY INFORMATION:** This proposed information collection was previously published in the **Federal Register** on May 19, 2021, page 27093 (Vol. 86 FR 27093) and allowed 60 days for public comment. No public comments were received. The National Cancer Institute (NCI), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

*Proposed Collection:* Evaluation of Office of Acquisitions System (OASYS)

and FFRDC Contract Administration System (FCAS) Vendor Portals National Cancer Institute (NCI), 0925–NEW, Expiration Date XX/XX/XXXX, NEW, National Cancer Institute (NCI), National Institutes of Health (NIH).

*Need and Use of Information Collection:* The National Cancer Institute (NCI) Office of Acquisitions (OA), located within the Office of the Director (OD) in the Office of Management (OM) at the National Cancer Institute (NCI), awards and administers contracts and simplified acquisitions in support of the Institute’s mission to prevent, diagnose and treat cancer. During the acquisition process, the OA ensures that customer service is paramount, and communications are open and continuous. Currently requests and correspondence are sent to and received from vendors through email with the exception of the FFRDC Contractor who submits through the FCAS Vendor Portal which is in production. To streamline processes, increase transparency and gain efficiencies, the OA developed OASYS and FCAS vendor portals to replace processes that are handled through

email (future OASYS Vendor Portal Users) and were (current FCAS Vendor Portal Users) to individual OA recipients. The FCAS Vendor Portal and in the future, the OASYS Vendor Portal will serve as a one-stop shop for transmission of requests, reports, deliverables and other correspondence due on numerous research and development, in support of R&D contracts as well as those contract vehicles awarded using various Federal Acquisition Procedures including but not limited to FAR Part 8, Required Sources of Supplies and Services, FAR Part 13, Simplified Acquisition Procedures, and FAR Part 12, Acquisition of Commercial Items. These reports and deliverables cover a wide variety of topics in the areas of cancer research including prevention, detection, diagnosis, and control.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 232.

**ESTIMATED ANNUALIZED BURDEN HOURS**

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average time per response (in hours)	Total annual burden hours
Survey—OASYS .....	Individuals .....	10	1	6/60	1
Survey—FCAS .....	Individuals .....	1	1	6/60	1
Registration—OASYS .....	Corporations .....	400	1	6/60	40
Registration—FCAS .....	Corporations .....	1	1	6/60	1
Data Field Information—OASYS .....	Individuals .....	400	18	1/60	120
Data Field Information—FCAS .....	Individuals .....	61	63	1/60	64
Add/Edit new Vendor User—OASYS .....	Corporations .....	40	1	6/60	4
Add/Edit new Vendor User—FCAS .....	Corporations .....	6	1	6/60	1
<b>Totals .....</b>	<b>.....</b>	<b>919</b>	<b>11,501</b>	<b>.....</b>	<b>232</b>

Dated: August 26, 2021.  
**Vivian Horovitch-Kelley**,  
*Project Clearance Liaison, National Cancer Institute, National Institutes of Health.*  
 [FR Doc. 2021–18767 Filed 8–30–21; 8:45 am]  
**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Environmental Health Sciences; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the National Heart, Lung, and Blood Advisory Council, August 31, 2021–September 1, 2021, National Institutes of Health, Bethesda,

Maryland, 20892, which was published in the **Federal Register** on August 4, 2021, FR Doc 2021–16549, 86 FR 41983.

This notice is being amended to change the start time for the second Open session on September 1, 2021, which will now be 12:30 p.m. and will still end at 2:30 p.m. as listed. The meeting is closed to the public.

Dated: August 25, 2021.  
**David W. Freeman**,  
*Program Analyst, Office of Federal Advisory Committee Policy.*  
 [FR Doc. 2021–18725 Filed 8–30–21; 8:45 am]  
**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Human Genome Research Institute; Notice of Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Human Genome Research.

The meeting will be open to the public as indicated below, the 94th meeting of the National Advisory Council for Human Genome Research open session will be livestreamed and available for viewing to the public from <https://www.genome.gov/event-calendar/94th-Meeting-of-National-Advisory-Council-for-Human-Genome->